Overall WORX gets a fundamental rating of 1 out of 10. We evaluated WORX against 35 industry peers in the Health Care Technology industry. Both the profitability and financial health of WORX have multiple concerns. WORX is valued expensive and it does not seem to be growing.

Quickly go to:

1. Profitability

2. Health

3. Growth

4. Valuation

5. Dividend

1. Profitability

1.1 Basic Checks

WORX had negative earnings in the past year.
WORX had a negative operating cash flow in the past year.
In the past 5 years WORX always reported negative net income.
WORX had a negative operating cash flow in each of the past 5 years.

1.2 Ratios

WORX's Return On Assets of -54.21% is on the low side compared to the rest of the industry. WORX is outperformed by 80.00% of its industry peers.
With a Return On Equity value of -64.87%, WORX is not doing good in the industry: 62.86% of the companies in the same industry are doing better.

		Industry Rank	Sector Rank
ROA	-54.21%
ROE	-64.87%
ROIC	N/A

ROA(3y)-33.77%

ROA(5y)-42.54%

ROE(3y)-51.97%

ROE(5y)-68.9%

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

With a Gross Margin value of 26.13%, WORX is not doing good in the industry: 77.14% of the companies in the same industry are doing better.
WORX's Gross Margin has improved in the last couple of years.
The Profit Margin and Operating Margin are not available for WORX so they could not be analyzed.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	26.13%

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3Y-14.52%

GM growth 5Y3.43%

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

WORX has more shares outstanding than it did 1 year ago.
The number of shares outstanding for WORX has been increased compared to 5 years ago.
The debt/assets ratio for WORX has been reduced compared to a year ago.

2.2 Solvency

WORX has an Altman-Z score of -4.94. This is a bad value and indicates that WORX is not financially healthy and even has some risk of bankruptcy.
WORX has a worse Altman-Z score (-4.94) than 77.14% of its industry peers.
WORX has a Debt/Equity ratio of 0.00. This is a healthy value indicating a solid balance between debt and equity.
WORX has a Debt to Equity ratio of 0.00. This is in the better half of the industry: WORX outperforms 62.86% of its industry peers.

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF	N/A
Altman-Z	-4.94

ROIC/WACCN/A

WACCN/A

2.3 Liquidity

WORX has a Current Ratio of 1.13. This is a normal value and indicates that WORX is financially healthy and should not expect problems in meeting its short term obligations.
With a Current ratio value of 1.13, WORX is not doing good in the industry: 80.00% of the companies in the same industry are doing better.
A Quick Ratio of 1.13 indicates that WORX should not have too much problems paying its short term obligations.
The Quick ratio of WORX (1.13) is worse than 80.00% of its industry peers.

		Industry Rank	Sector Rank
Current Ratio	1.13
Quick Ratio	1.13

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 65.24% over the past year.
The Revenue for WORX has decreased by -13.63% in the past year. This is quite bad
WORX shows a very negative growth in Revenue. Measured over the last years, the Revenue has been decreasing by -11.64% yearly.

EPS 1Y (TTM)65.24%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%43.28%

Revenue 1Y (TTM)-13.63%

Revenue growth 3Y-13.57%

Revenue growth 5Y-11.64%

Sales Q2Q%-6.54%

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

EPS Next YN/A

EPS Next 2YN/A

EPS Next 3YN/A

EPS Next 5YN/A

Revenue Next YearN/A

Revenue Next 2YN/A

Revenue Next 3YN/A

Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.